Cheplapharm Arzneimittel GmbH

Industry

  • Pharmaceuticals
    • Specialty Pharmaceuticals
    • Nutraceuticals
  • Biotechnology
    • Drug Discovery Technologies
      • Molecular Diversity
        • Natural Products
See more in Biomedtracker

Latest on Cheplapharm Arzneimittel GmbH

In Vivo

Deal Volume Up, Value Down During The First Half

 
• By Joseph Haas

The biopharmaceutical industry’s preference for targeted, bolt-on acquisitions seemed to take hold even more strongly during the first half of 2024, as merger-and-acquisition deal volume increased by

Scrip

Deal Volume Up, Value Down During The First Half

 
• By Joseph Haas

The biopharmaceutical industry’s preference for targeted, bolt-on acquisitions seemed to take hold even more strongly during the first half of 2024, as merger-and-acquisition deal volume increased by

Scrip

Deal Watch: Merck KGaA Enhances Cell/Gene Therapy Capabilities With Mirus Takeout

 
• By Joseph Haas, Vibha Ravi, and Dexter Jie Yan

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Merck KGaA Pays $600m For Transfection

Scrip

Asia Deal Watch: SciClone Obtains Commercial Rights In China To Menarini Breast Cancer Drug

 
• By Vibha Ravi, Jung Won Shin, Lisa Takagi, Dexter Jie Yan, and Joseph Haas

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Menarini, SciClone Will Partner On